Enanta Pharmaceuticals | ENTA - Le Chiffre D'Affaires De Vente





Ventes Changement Date
AbbVie USD 15B 1.62B 2026-03
Amgen USD 8.62B 1.28B 2026-03
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 15.29B 213M 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Biogen USD 2.25B 30M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.93B 130M 2025-12
GlaxoSmithKline GBP 7.63B 991M 2026-03
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 40.59M 2.38M 2025-12
Incyte USD 1.27B 240M 2026-03
Insmed USD 263.8M 121.8M 2025-12
Ionis Pharmaceuticals USD 246M 43M 2026-03
J&J USD 24.1B 500M 2026-03
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
Merck USD 16.29B 110M 2026-03
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 13.11B 226M 2026-03
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 164.7M 46.3M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Vertex Pharmaceuticals USD 2.99B 200M 2026-03